Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.

Nanobiotix S.A.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PARIS AND CAMBRIDGE, MASS., JULY 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY PIONEERING PHYSICS-BASED APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED TWO IMPORTANT DEVELOPMENTS THAT AIM TO REINFORCE THE GLOBAL POSITIONING OF POTENTIAL FIRST-IN-CLASS RADIOENHANCER JNJ-1900 (NBTXR3), WHICH IS LICENSED BY JANSSEN PHARMACEUTICA NV, A JOHNSON & JOHNSON COMPANY.

NANOBIOTIX ANNOUNCES REGULATORY HARMONIZATION AND NEW COMPOSITION OF MATTER PATENT FILED FOR JNJ-1900 (NBTXR3)

PARIS AND CAMBRIDGE, MASS., MAY 28, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-CLINICAL STAGE BIOTECHNOLOGY COMPANY PIONEERING NANOPARTICLE-BASED APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, ANNOUNCED TODAY THAT COMPANY MANAGEMENT WILL PARTICIPATE IN FIRESIDE CHATS AT FOLLOWING CONFERENCE:

NANOBIOTIX TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE INVESTOR CONFERENCE

PARIS AND CAMBRIDGE, MASS., MAY 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO - NASDAQ: NBTX - THE COMPANY), A LATE-CLINICAL STAGE BIOTECHNOLOGY COMPANY PIONEERING NANOTHERAPEUTIC APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, TODAY PROVIDED AN UPDATE ON OPERATIONAL PROGRESS AND REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER OF 2025.

NANOBIOTIX PROVIDES FIRST QUARTER 2025 OPERATIONAL AND FINANCIAL UPDATE

PARIS AND CAMBRIDGE, MASS., MAY 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-CLINICAL STAGE BIOTECHNOLOGY COMPANY PIONEERING NANOPARTICLE-BASED APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, ANNOUNCED TODAY THAT COMPANY MANAGEMENT WILL PARTICIPATE IN FIRESIDE CHATS AT FOLLOWING CONFERENCE:

NANOBIOTIX TO PARTICIPATE IN THE H.C. WAINWRIGHT 3RD ANNUAL BIOCONNECT INVESTOR CONFERENCE AT NASDAQ

RESULTS DEMONSTRATED FAVORABLE SAFETY, INJECTION FEASIBILITY, AND ENCOURAGING ONCOLOGIC OUTCOMES IN PATIENTS (N=22) WITH LOCALLY ADVANCED OR BORDERLINE RESECTABLE PANCREATIC CANCER MEDIAN OVERALL SURVIVAL OF 23 MONTHS FROM DATE OF DIAGNOSIS [95% CI; 17 MONTHS  NOT REACHED] MEDIAN LOCAL PROGRESSION-FREE SURVIVAL OF 13.3 MONTHS FROM COMPLETION OF RADIATION NOTABLE FINDINGS OBSERVED IN EXPLORATORY BIOMARKER ANALYSES INCLUDE: AN ASSOCIATION BETWEEN INCREASED CIRCULATING TUMOR MUTATIONAL BURDEN (CTMB) AND LPFS AND OS CA19-9 NORMALIZATION IN 59% OF PATIENTS IN THE STUDY, AND AN ASSOCIATION BETWEEN CA19-9 NORMALIZATION AND OS FIRST PATIENT INJECTED IN A NEW COHORT THAT ADDS STANDARD-OF-CARE CONCURRENT CHEMOTHERAPY (CAPECITABINE OR 5-FU) TO RADIOTHERAPY-ACTIVATED JNJ-1900 (NBTXR3) AND RECRUITMENT IS ONGOING INVESTIGATORS CONCLUDED THAT THESE RESULTS SUPPORT FURTHER EVALUATION IN A RANDOMIZED STUDY DATA PRESENTED AT THE 2025 ANNUAL MEETING OF THE EUROPEAN SOCIETY OF RADIATION ONCOLOGY PARIS AND CAMBRIDGE, MASS., MAY 05, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY PIONEERING NANOTHERAPEUTIC APPROACHES TO IMPROVE TREATMENT OUTCOMES FOR PATIENTS WITH CANCER, TODAY ANNOUNCED THE PRESENTATION OF FULL RESULTS FROM THE COMPLETED DOSE ESCALATION AND DOSE EXPANSION PHASES OF A PHASE 1 STUDY EVALUATING JNJ-1900 (NBTXR3) IN PATIENTS WITH LOCALLY ADVANCED OR BORDERLINE RESECTABLE PANCREATIC CANCER.

NANOBIOTIX ANNOUNCES FULL RESULTS FROM COMPLETED PHASE 1 STUDY EVALUATING JNJ-1900 (NBTXR3) IN PANCREATIC CANCER

PARIS ANDCAMBRIDGE, MASS., APRIL 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-CLINICAL STAGE BIOTECHNOLOGY COMPANY PIONEERING NANOPARTICLE-BASED THERAPEUTIC APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, TODAY ANNOUNCED THE PRESENTATION OF FULL RESULTS FROM THE COMPLETED DOSE ESCALATION AND DOSE EXPANSION PARTS OF A PHASE 1 STUDY EVALUATING JNJ-1900 (NBTXR3) IN PATIENTS WITH LOCALLY ADVANCED OR BORDERLINE RESECTABLE PANCREATIC CANCER. THE STUDY, CONDUCTED BY THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, WILL BE PRESENTED BY PRINCIPAL INVESTIGATOR DR. EUGENE KOAY ON SUNDAY, MAY 4TH AT 11:00 AM EDT / 5:00PM CEST DURING THE 2025 ANNUAL MEETING OF THE EUROPEAN SOCIETY FOR RADIOTHERAPY AND ONCOLOGY (ESTRO 2025).

NANOBIOTIX ANNOUNCES PRESENTATION OF FULL RESULTS FROM COMPLETED PHASE 1 STUDY EVALUATING JNJ-1900 (NBTXR3) IN PANCREATIC CANCER FOLLOWED BY A CONFERENCE CALL

GLOBAL DEVELOPMENT PROGRAM FOR JNJ-1900 (NBTXR3) PROCEEDING AS PLANNED, WITH OPPORTUNITY TO ADDRESS ONE OF THE LARGEST UNTAPPED MARKETS IN ONCOLOGY THROUGH LEAD PROGRAMS IN HEAD AND NECK CANCER AND LUNG CANCER DISCIPLINED FINANCIAL STRATEGY TOWARD LONG-TERM SUSTAINABILITY AND GROWTH CONTINUES TO STRENGTHEN FINANCIAL POSITION THROUGH FOCUSED ALLOCATION OF CAPITAL, THE RECEIPT OF A PLANNED MILESTONE PAYMENT, THE TRANSFER OF SPONSORSHIP FOR NANORAY-312, AND AN AMENDMENT TO THE GLOBAL LICENSING AGREEMENT FOR JNJ-1900 (NBTXR3) CURADIGM, A NEXT GENERATION NANOTHERAPEUTIC PLATFORM DESIGNED TO RESHAPE DRUG DESIGN AND DEVELOPMENT ACROSS MULTIPLE THERAPEUTIC CLASSES AND DISEASE AREAS, HAS LAUNCHED CASH RUNWAY EXTENDED INTO MID-2026 AND REDUCTION OF OPERATIONAL CASH BURN EXPECTED BEYOND MID-2026 WITH 49.7 MILLION IN CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2024 CLINICAL DATA READOUTS IN 2025 FROM PHASE 1 AND 2 STUDIES IN RM-HNSCC, PANCREATIC CANCER, NSCLC AMENABLE TO RE-IRRADIATION, MELANOMA AND ESOPHAGEAL CANCER CONFERENCE CALL AND WEBCAST SCHEDULED FOR APRIL 3, 2025 AT 8:00 A.M. EDT / 2:00 P.M.

NANOBIOTIX PROVIDES BUSINESS UPDATE AND REPORTS FULL YEAR 2024 FINANCIAL RESULTS

CONFERENCE CALL AND WEBCAST SCHEDULED FOR THURSDAY, APRIL 3, 2025, AT 8:00 AM EDT / 2:00 PM CEST CONFERENCE CALL AND WEBCAST SCHEDULED FOR THURSDAY, APRIL 3, 2025, AT 8:00 AM EDT / 2:00 PM CEST

NANOBIOTIX TO ANNOUNCE FOURTH QUARTER AND FULL YEAR 2024 OPERATIONAL AND FINANCIAL UPDATE ON APRIL 2, 2025

PARIS AND CAMBRIDGE, MASS., MARCH 27, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-STAGE CLINICAL BIOTECHNOLOGY COMPANY PIONEERING DISRUPTIVE, NANOTHERAPEUTIC APPROACHES TO REVOLUTIONIZE TREATMENT OUTCOMES FOR MILLIONS OF PATIENTS, TODAY ANNOUNCED THE FIRST DATA FROM THE COMPLETED DOSE ESCALATION PART OF A PHASE 1 STUDY SPONSORED BY THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER ("MD ANDERSON") EVALUATING RADIOTHERAPY-ACTIVATED NBTXR3 (JNJ-1900)1 AS A SECOND OR LATER LINE (2L+) THERAPY FOR PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) AMENABLE TO RE-IRRADIATION. THESE DATA WILL BE PRESENTED AT THE 2025 EUROPEAN LUNG CANCER CONFERENCE BY STUDY PRINCIPAL INVESTIGATOR DR. SAUMIL GANDHI.

NANOBIOTIX ANNOUNCES FIRST DATA FROM THE COMPLETED DOSE ESCALATION PART OF A PHASE 1 STUDY EVALUATING NBTXR3 (JNJ-1900) AS A 2L+ THERAPY FOR PATIENTS WITH LOCALLY ADVANCED NSCLC

PARIS AND CAMBRIDGE, MASS., MARCH 20, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (EURONEXT: NANO  NASDAQ: NBTX  THE COMPANY''), A LATE-CLINICAL STAGE BIOTECHNOLOGY COMPANY PIONEERING NANOPARTICLE-BASED THERAPEUTIC APPROACHES TO EXPAND TREATMENT POSSIBILITIES FOR PATIENTS WITH CANCER AND OTHER MAJOR DISEASES, TODAY ANNOUNCED POSTER PRESENTATIONS FROM TWO PHASE 1 STUDIES EVALUATING JNJ-1900 (NBTXR3) FOR PATIENTS WITH LUNG CANCER (NSCLC) TO BE PRESENTED AT THE 2025 EUROPEAN LUNG CANCER CONFERENCE (ELCC).

Nanobiotix S.A.

NBTX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Nanobiotix S.A.

NBTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NBTX